Anti-inflammatory,
analgesic, and anti-pyretic activities of orally administered
etofenamate, the
diethylene glycol ester of
flufenamic acid, were investigated in experimental animals. Against
acetic acid-induced vascular permeability in mice and ultra-violet light-induced
erythema in guinea pigs,
etofenamate produced a dose related inhibition at doses of 40--320 mg/kg and 5--20 mg/kg, respectively. In rats, felt-pellet-induced
granuloma formation and adjuvant-induced
arthritis were significantly inhibited by repeated administration of
etofenamate at doses of 20 mg/kg/day for 5 days and 40 mg/kg/day for 21 days, respectively.
Etofenamate showed an inhibitory activity on the squeak response caused by flexing and extending the
silver nitrate-induced arthritic joint in rats; and it produced a dose related anti-writhing activity at doses of 50--300 mg/kg and 10--80 mg/kg in mice and rats, respectively, in the
acetic acid-induced writhing test.
Etofenamate showed a significant anti-pyretic activity at doses of 0.2 mg/kg or more. These potencies of
etofenamate were 0.5 to 1.6 times those of
flufenamic acid. In particular, the anti-
erythema, anti-
arthritis, and anti-pyretic activities of
etofenamate were approximately equivalent to or superior to those of
flufenamic acid. From these results, it was suggested that
etofenamate given orally, like other non-steroidal anti-inflammatory drugs, showed anti-inflammatory,
analgesic, and anti-pyretic activities in experimental animals.